A randomized, double-blind, active- and placebo-controlled, parallel group, multicenter study to evaluate the efficacy and safety of multiple doses of CG5503 [tapentadol] immediate release formulation in the treatment of acute pain from total hip replacement surgery followed by a voluntary open-label extension.

Trial Profile

A randomized, double-blind, active- and placebo-controlled, parallel group, multicenter study to evaluate the efficacy and safety of multiple doses of CG5503 [tapentadol] immediate release formulation in the treatment of acute pain from total hip replacement surgery followed by a voluntary open-label extension.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 26 Aug 2014

At a glance

  • Drugs Tapentadol (Primary) ; Oxycodone
  • Indications Postoperative pain
  • Focus Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 01 Dec 2008 Additional trial identifiers R331333PAI3001 and KF5503-31 reported by ClinicalTrials.gov.
    • 01 Dec 2008 Actual patient number reported as 365 by ClinicalTrials.gov.
    • 17 Jan 2008 Status changed from recruiting to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top